



**Amendment to
pharmacoepidemiological study protocol
ER-9489**

**A retrospective nationwide cohort study to investigate
the treatment of type 2 diabetic patients in Finland -
DAHLIA**

Authors:	Ilona Iso-Mustajärvi, Housseem Khanfir, Fabian Hoti, Tuire Prami
Protocol number:	ER-9489
Sponsor:	AstraZeneca Nordic Baltic
Protocol version:	2.1
Protocol date:	07 Jun 2016
Amendment version:	1.0
Amendment date:	03 May 2017

This is an Amendment version 1.0 to study protocol version 2.1:

1 Amendments and updates

The following amendments have been done compared to the protocol version 2.1 dated 07 Jun 2016.

Issue number	Section of study protocol	Amendment or update	Reason
1.	2 Responsible parties	Name of the Principal investigator changed from Tuire Prami to Fabian Hoti	Administrative changes
2.	2 Responsible parties	Name of the member of Study scientific committee changed from Tuire Prami to Fabian Hoti	Administrative changes

2 Approvals

We have reviewed this amendment version 1.0 to study protocol version 2.1 (ER-9489, Version 1.0, dated 02 May 2017) and agree to its terms by signing it.

Principal investigator:



 

Signature Date

Fabian Hoti

EPID Research, Metsänneidonkuja 12, FI-02130 Espoo



Medical experts of the study scientific committee:

Signature Date

Jorma Lahtela

Tampere University Hospital, Internal Medicine, P.O. Box 2000 FI-33521 Tampere

Signature Date

Johan Eriksson

Tukholmankatu 8 B (Biomedicum 2B), PO Box 20, 00014 University of Helsinki, Finland

On behalf of the sponsor:

Signature

Date

Johan Bodegård

CONFIDENTIAL